drugset
Drugs / Claudin18.2 Targeted Activated Dendritic Cells
last change Feb 2026 re-read 3 minutes ago

Claudin18.2 Targeted Activated Dendritic Cells

Cell therapy

Developed for
pancreatic neoplasm
Investigated by
Frontiergate Biopharm（Hainan） Co., LTD · Hainan Cancer Hospital

Trials 1

today NCT07416240 · Ph 0
20272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT07416240 Feb 2026 → Feb 2028 expected pancreatic neoplasm Hainan Cancer Hospital Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Claudin18.2 Targeted Activated Dendritic Cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT07416240 ↗
Modality Cell therapy “Autologous dendritic cells (DCs) genetically modified to express Claudin18.2 chimeric antigen receptor (CAR) and activation domain” NCT07416240 ↗